Independent Prognostic Value of Serum Markers in Diffuse Large B-Cell Lymphoma in the Era of the NCCN-IPI

• DOI: 10.6004/jnccn.2015.0178
• Publication Date: 2017-04-14T12:06:28Z
• Authors: Thomas Melchardt; Katharina Troppan; Lukas Weiss; Clemens Hufnagl; Daniel Neureiter; Wolfgang Tränkens...; Konstantin Schlick; Florian Huemer; Alexander Deutsch; Peter Neumeister; Richard Greil; Martin Pichler; Alexander Egle
• Keywords: Chemoimmunotherapy; International Prognostic Index

Background: Several serum parameters have been evaluated for adding prognostic value to clinical scoring systems in diffuse large B-cell lymphoma (DLBCL), but none of the reports used multivariate testing more than one parameter at a time. The goal this study was validate widely available their independent impact era National Comprehensive Cancer Network–International Prognostic Index (NCCN-IPI) score determine which were most useful. Patients and Methods: This retrospective bicenter analysis includes 515 unselected patients with DLBCL who treated rituximab anthracycline-based chemoimmunotherapy between 2004 January 2014. Results: Anemia, high C-reactive protein, bilirubin levels had an survival analyses addition NCCN-IPI, whereas neutrophil-to-lymphocyte ratio, gamma-glutamyl transferase levels, platelets-to-lymphocyte ratio did not. Conclusions: In our cohort, we describe promising markers improve NCCN-IPI. Anemia protein retain power even negative role may be associated as marker liver function. Further studies are warranted incorporate these into models define opposite novel molecular markers.